Innovative Medicines Initiative 2.0 – Call 20: Tumor plasticity

Grant Name
Innovative Medicines Initiative 2.0 – Call 20: Tumor plasticity
Funder
Österreichische Forschungsförderungsgesellschaft
Country or Region
Austria
Research Field
Medicine, Oncology
Biochemistry, Genetics and Molecular Biology, Cancer Research
Deadline
April 21, 2020 (Expired)
Grant Size
Up to 7,058,000 EUR with total funding of 140,209,500 EUR
Contact Info
Dr.Haberl,Ines ines.haberl@ffg.at
Eligibility
Small and Medium Businesses
Grant Number
IMI2-2020-20-04
Description
The last decade has seen tremendous advances in the development of effective targeted therapies as well as in immuno-oncology to more effectively treat cancer. Despite this, cures are still rare in the metastatic setting. In most cases, an initial response to treatment is followed by the eventual emergence of drug resistance [1]. Drug resistance in cancer is one of the greatest causes of mortality, and despite increasing success with targeted therapies in the clinic (including immunotherapy), the mechanisms by which cancer cells evade cell death are still not well understood. Drug combinations are likely to be critical to overcoming drug resistance but are dependent on identifying the cellular programmes that cancer cells use to resist therapeutic agents.

Funding resources

Purdue Grant Writing Lab: Introduction to Grant Writing Open Link
University of Wisconsin Writing Center: Planning and Writing a Grant Proposal Open Link

Quick share


Add deadline to calendar

April 21, 2020

Have a funding opportunity that you want to list here?

Submit the grant details to support@peeref.com for review and listing.


Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Related opportunities

Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Not Allowed)
Health Sep 13, 2024 12:00:00 AM EDT $500,000
DoD Peer Reviewed Orthopaedic, Clinical Trial Award
Science and Technology and other Researc... Sep 17, 2024 12:00:00 AM EDT 13250000
Demonstration of approaches by regions and local authorities focused on increasing climate resilience of the most vulnerable social groups (just climate resilience)
Environment, Pollution & Climate 2024-09-18 €22500000
European Partnership: One Health Anti-Microbial Resistance
Antimicrobial resistance 2024-09-25 €100000000
DoD Multiple Sclerosis, Investigator-Initiated Research Award
Science and Technology and other Researc... Oct 07, 2024 12:00:00 AM EDT 6000000
DoD Bone Marrow Failure, Idea Development Award
Science and Technology and other Researc... Oct 09, 2024 12:00:00 AM EDT 4240000
Zero-pollution cities
Artificial Intelligence 2025-01-16 €20000000
Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)
Health Jun 06, 2025 12:00:00 AM EDT $295,924
Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
Health Sep 05, 2025 12:00:00 AM EDT $1,838,436
Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Optional)
Health Sep 14, 2026 12:00:00 AM EDT 500000